Oxybutynin for Excessive Sweating: What Placebo Trials Measured

An oral medicine may enter the treatment discussion when sweating affects several areas, local treatments have failed or another treatment needs support. The American Academy of Dermatology¹ lists oral oxybutynin among these options, after assessment of the sweating pattern and cause.¹

Its effects extend beyond the area you want drier. The trial results are worth reading alongside dry mouth, bladder and bowel effects, and reduced ability to cool yourself.¹

The French trial counted a change on a symptom scale

The 2015 French trial² randomized 62 adults with localized or generalized hyperhidrosis. Most, 83%, had the generalized form. Oxybutynin began at 2.5 mg daily and increased to a maximum of 7.5 mg daily.²

Here, generalized meant two or more affected locations, rather than necessarily every part of the body. NICE’s³ evidence table reports 58 people analyzed at six weeks. Average age was about 35, and the French Society of Dermatology partly funded the study.³

60% taking oxybutynin improved by at least one point on the Hyperhidrosis Disease Severity Scale, versus 27% taking placebo. This four-point symptom scale describes how tolerable sweating is and how much it interferes with daily activities. The result does not mean 60% became sweat-free.²⁴

NICE’s³ appraisal notes that no objective sweat measurement was used. A reported improvement on the scale should not be rewritten as an exact percentage reduction in sweat volume. The trial was small and short, and the appraisal found uncertainty about allocation concealment.³

Dry mouth occurred in 43% with oxybutynin versus 11% with placebo. That is a separate outcome from sweating improvement. Both can happen to the same person; the study does not tell you whether that trade-off will suit you.²

The Brazilian trial used a different success definition

In a 2012 Brazilian study⁵, 50 people were assigned treatment and 45 completed six weeks: 23 taking oxybutynin and 22 taking placebo. Thirty-three completers were women, and average ages were about 28. The protocol increased oxybutynin to 10 mg daily.⁵

Participants scored perceived improvement from 0 to 10. Seventeen of 23 oxybutynin recipients, versus six of 22 placebo recipients, reported moderate or great improvement in palm or underarm sweating. Those categories are not the French trial’s one-point HDSS threshold, so the two response percentages should not be ranked as though they measured identical outcomes.⁵

At the higher dose, moderate or severe dry mouth affected 34.8% versus 9.1%. The study relied on self-reported sweating, lost five participants and followed treatment for only six weeks. It did not establish years of benefit or safety.⁵

A 2026 comparison was too small to settle treatment choice

The TODAY trial compared oral oxybutynin, a 10% oxybutynin spray and placebo spray for 35 days. It randomized 17 people, with 14 completing, including only four oral-treatment participants. Treatment was open-label, with blinded endpoint assessment.⁴

No significant between-group difference in sweating-severity scores emerged. A quality-of-life improvement within the active-spray group did not establish that it outperformed the other groups. Eligibility was restricted to ages 18 to 45, excluding menopause symptoms. The Science Valley Research Institute provided support. This exploratory study cannot establish equivalence or rank the treatments.⁴

Prescribing requires more than choosing a trial dose

The current US tablet label lists bladder symptoms as its indication; using it for sweating is off-label. It contraindicates urinary retention, gastric retention or severe reduced gut movement, and uncontrolled narrow-angle glaucoma. It also warns about confusion and drowsiness, particularly after starting or increasing treatment.⁶

The label warns that reduced sweating can contribute to heat stroke in high temperatures. Other medicines with anticholinergic effects can add to adverse effects. Bring a complete medicine list and discuss outdoor work, exercise and hot-weather plans before a prescription is agreed.⁶ Our oral sweat-medicine heat guide covers that conversation.

The Academy advises tailoring the dose to the person and using the lowest amount that helps. It also notes that continued benefit requires continued use. Improvement during six weeks of tablets does not demonstrate a permanent change after stopping.¹

Set a specific review target

In “The Step-Up Conversation” in Arms Up, the visit starts with your worst sweating zone, its four-point score, the pattern and what you have tried. Bring those details, then name one task you want treatment to make easier, such as handling paper or avoiding a midday shirt change.

Ask when to review that task and your symptom score, which side effects require contact and what would lead the prescriber to change the plan. A lower sweating score is useful only alongside whether the treatment remains tolerable in your daily life.